1,5-辛二醇 | 2736-67-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 1,5-辛二醇
• 英文名称: 1,5-octanediol
• 英文别名: octane-1,5-diol；Octan-1,5-diol
• CAS: 2736-67-6
• 化学式: C₈H₁₈O₂
• 分子量: 146.23
• InChiKey: ZKRNQSNKDPEUOH-UHFFFAOYSA-N

物化性质

• 沸点：
  144-146 °C
• 密度：
  0.950 g/cm3(Temp: 17 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,5-辛二醇 在 pyridinium chlorochromate 作用下， 生成 5-oxo-octanal
  参考文献：
  名称：

  Synthesis and Occurrence of Oxoaldehydes in Used Frying Oils

  摘要：

  As part of our efforts to identify volatile decomposition products in used frying oils, a series of 4- and 5-oxoaldehydes were synthesized, purified, and characterized by gas chromatography, gas chromatography-mass spectrometry, gas chromatography-Fourier transform infrared spectrometry, and nuclear magnetic resonance spectrometry. Oxoaldehydes have been proposed as possible precursors of alkylfurans, which have potential anticancer effects. In a model reaction 4-oxononanal was refluxed in hexane for 40 days and only trace amounts of 2-pentylfuran were produced, suggesting that it is not a major precursor of the furan. The volatile constituents of used frying oils obtained from commercial food processors were studied, and 4-oxohexanal, 4-oxooctanal, 4-oxononanal, and 4-oxodecanal were identified.

  DOI：

  10.1021/jf00049a006
• 作为产物：
  描述：

  1,5-辛内酯 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 20.0h， 以73%的产率得到1,5-辛二醇
  参考文献：
  名称：

  单链1,32-烷基支链双（磷酸胆碱）的合成和聚集行为：侧链长度的影响†

  摘要：

  已经合成了三个新的单链双（磷酸胆碱），其具有邻近首基的两个可变长度的侧链烷基，作为天然存在的古细菌膜脂质的模型脂质。使用伯溴化物作为侧部分和1，ω-二溴化物作为中心部分的Cu催化格氏双偶联反应实现了合成。我们可以证明，所产生的bolalipids的聚集行为在很大程度上取决于烷基侧链的长度：C3分支的bolalipid自组装成层状薄片，而C6-和C9-类似物形成纳米纤维。形成薄片的bolalipids将来可用于制备稳定和量身定制的脂质体，用于口服药物递送。

  DOI：

  10.1039/c8ob00424b

文献信息

• Chemo- and Regioselective Synthesis of Acyl-Cyclohexenes by a Tandem Acceptorless Dehydrogenation-[1,5]-Hydride Shift Cascade
  作者：Lewis B. Smith、Roly J. Armstrong、Daniel Matheau-Raven、Timothy J. Donohoe

  DOI：10.1021/jacs.9b12296

  日期：2020.2.5

  acceptorless dehydrogenation of the diol followed by a redox-neutral cascade process, which is independent of the iridium catalyst. Deuterium labeling studies established that the key step of this cascade involves a novel base-mediated [1,5]-hydride shift. The cyclohexenyl ketone products could readily be cleaved under mildly acidic conditions to access a range of valuable substituted cyclohexene derivatives

  描述了一种从五甲基苯乙酮和 1,5-二醇中获得取代的酰基环己烯的原子经济方法。该过程由铱 (I) 催化剂与庞大的富电子膦配体 (CataCXium A) 共同催化，该配体有利于无受体脱氢反应，而不是共轭还原成相应的环己烷。该反应产生水和氢气作为唯一的副产物，并且可以使用该方法以非常高的产率合成范围广泛的官能化酰基环己烯产物。进行了一系列对照实验，结果表明该过程是由二醇的无受体脱氢引发的，然后是氧化还原中性级联过程，该过程与铱催化剂无关。氘标记研究表明，该级联的关键步骤涉及一种新型碱介导的 [1,5]-氢化物转移。环己烯基酮产物在弱酸性条件下很容易裂解，以获得一系列有价值的取代环己烯衍生物。
• Further studies on the utility of sodium hypochlorite in organic synthesis. Selective oxidation of diols and direct conversion of aldehydes to esters
  作者：Robert V. Stevens、Kevin T. Chapman、Cheryl A. Stubbs、Weyton W. Tam、Kim F. Albizati

  DOI：10.1016/s0040-4039(00)85677-4

  日期：1982.1

  Sodium hypochlorite in acetic acid solution selectively oxidizes secondary alcohols to ketones in the presence of primary alcohols and converts aldehydes to methyl esters in the added presence of methanol.

  在乙酸溶液中的次氯酸钠在伯醇存在下选择性地将仲醇氧化为酮，在甲醇存在下将醛转化为甲酯。
• Cobalt Pincer Complexes for Catalytic Reduction of Carboxylic Acid Esters
  作者：Kathrin Junge、Bianca Wendt、Andrea Cingolani、Anke Spannenberg、Zhihong Wei、Haijun Jiao、Matthias Beller

  DOI：10.1002/chem.201705201

  日期：2018.1.24

  A selection of cobalt(I) and cobalt(II) pincer type complexes with different substitution patterns was tested in the catalytic reduction of carboxylic acid esters to alcohols. The cobalt pincer type complex 4 is suitable for the hydrogenation of aromatic as well as aliphatic and cyclic esters. Mechanistic investigation indicated a metal ligand cooperated reaction pathway.

  在将羧酸酯催化还原为醇的过程中，测试了具有不同取代方式的钴（I）和钴（II）钳型复合物的选择。钴钳型配合物4适用于芳族以及脂族和环状酯的氢化。机理研究表明金属配体协同反应途径。
• Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
  申请人：Buck A. Elizabeth

  公开号：US20070280928A1

  公开（公告）日：2007-12-06

  The present invention provides a method for treating NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein the agent is an mTOR inhibitor, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein said agent is an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. The present invention also provides a pharmaceutical composition comprising an EGFR kinase inhibitor and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing the methods of this invention is the compound erlotinib HCl (also known as TARCEVA®).

  本发明提供了一种治疗患者体内NSCL、胰腺、结肠或乳腺癌肿瘤或肿瘤转移的方法，包括向患者同时或顺序给予治疗有效量的EGFR激酶抑制剂和一种使肿瘤细胞对EGFR激酶抑制剂产生敏感性的药物的组合，其中该药物是mTOR抑制剂，可以附加其他药物或治疗，如其他抗癌药物或放射治疗。本发明还提供了一种治疗患者体内肿瘤或肿瘤转移的方法，包括向患者同时或顺序给予治疗有效量的EGFR激酶抑制剂和一种使肿瘤细胞对EGFR激酶抑制剂产生敏感性的药物的组合，其中该药物是一种能够结合并直接抑制mTORC1和mTORC2激酶的mTOR抑制剂。本发明还提供了一种制药组合物，包括一种能够结合并直接抑制mTORC1和mTORC2激酶的EGFR激酶抑制剂和mTOR抑制剂，以及一种药用载体。本发明中可用于实施该方法的EGFR激酶抑制剂的首选示例是化合物厄洛替尼盐酸盐（也称为TARCEVA®）。
• [EN] 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTEINE KINASE HETEROBICYCLIQUES A SUBSTITUTION DE NOYAU BICYCLIQUE 6,6
  申请人：OSI PHARM INC

  公开号：WO2005097800A1

  公开（公告）日：2005-10-20

  Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein XI, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

  该式(I)的化合物及其药用可接受的盐，其中XI、X2、X3、X4、X5、X6、X7、R1和Q1在此处定义，抑制IGF-1R酶，可用于治疗和/或预防高增殖性疾病，如癌症、炎症、牛皮癣、过敏/哮喘、免疫系统疾病和疾病及中枢神经系统疾病和状况。